Drug Interactions with New and Investigational Antiretrovirals

被引：7

作者：

Crauwels, Herta M. ^{[1
]}

Kakuda, Thomas N. ^{[2
]}

机构：

[1] Tibotec BVBA, Mechelen, Belgium

[2] Tibotec Inc, Yardley, PA USA

来源：

CLINICAL PHARMACOKINETICS | 2010年 / 49卷 / 01期

关键词：

Fluconazole; Itraconazole; Dose Adjustment; Ketoconazole; Nucleoside Analogue;

D O I：

10.2165/11531240-000000000-00000

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：67 / 68

页数：2

共 12 条

[1]

Brown KC, 2009, CLIN PHARMACOKINET, V48, P554

[2] Drug Interactions with New and Investigational Antiretrovirals [J].

Brown, Kevin C. ;

Paul, Sunita ;

Kashuba, Angela D. M. .

CLINICAL PHARMACOKINETICS, 2009, 48 (04) :211-241

[3]

HOETELMANS R, 2005, 10 EUR AIDS C NOV 17

[4]

*JANSS CIL LTD, 2009, INT ETR TABL SUMM PR

[5] Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers [J].

Kakuda, T. N. ;

Scholler-Gyure, M. ;

De Smedt, G. ;

Beets, G. ;

Aharchi, F. ;

Peeters, M. P. ;

Vandermeulen, K. ;

Woodfall, B. J. ;

Hoetelmans, R. M. W. .

HIV MEDICINE, 2009, 10 (03) :173-181

[6]

PISCITELLI SC, 2002, 42 INT C ANT AG CHEM

[7]

Scholler-Gyure M.KakudaTN, 2009, 49 INT C ANT AG CHEM

[8]

SCHOLLERGYURE M, 2006, 8 INT C DRUG THER HI

[9]

*TIB INC, 2008, INT ETR TABL US PRES

[10]

*TIB PHARM IR, TMC125 TIDP2 C238 EX

← 1 2 →